Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Stock Transactions

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Summary

• On June 3, 2024, Atabak Mokari, the CFO of Corcept Therapeutics, reported transactions involving the company's common stock.
• 571 shares were disposed of to cover tax withholding obligations at a price of $30.17 per share.
• Mokari acquired 1,448 shares through a purchase plan at $31.3 per share.
• Additionally, 1,448 shares were acquired under unvested restricted stock awards granted through the purchase plan at $0.00.
• Following these transactions, Mokari directly owns 11,861 shares, which includes unvested restricted stock awards.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine stock transactions by the CFO, including tax-related disposals and participation in a company purchase plan. There's no indication of unusual or concerning activity.

Positives

• The acquisition of shares through the purchase plan demonstrates the CFO's investment in the company's stock.
• The purchase plan incentivizes long-term ownership, as the restricted stock awards vest after one year of continued ownership of the purchased shares.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's confidence in the company's prospects.

Key Dates